Mieloma Multiple - Mieloma.com

He recibido esta noticia de SamartBrief(IMF)
Cita:
"Cancer Treat Rev. 2008 Mar 30
    A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
    Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K; on behalf of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care.

    Keenan Research Centre, Li Ka Shing Knowledge Institute and Division of Hematology/Oncology, St. Michael’s Hospital, 30 Bond Street, Room 2065Q, Toronto, ON, Canada M5B 1W8.

    A systematic review and meta-analysis was performed to determine the efficacy and toxicity of thalidomide in previously untreated patients with myeloma. Medline, Embase, Cochrane Controlled Trials Register, and abstracts from the American Society of Hematology and the American Society of Clinical Oncology were searched for randomized controlled trials (RCTs) of either induction or maintenance thalidomide in adults with previously untreated myeloma. Nine RCTs of induction thalidomide, three RCTs of maintenance thalidomide, and one RCT of induction and maintenance thalidomide were identified, involving a total of 4144 subjects. When thalidomide was added to standard, non-transplantation myeloma therapy, overall survival (OS) improved (HR 0.67; 95% CI 0.56-0.81). When thalidomide was given as maintenance following autologous transplantation (ASCT), there was a trend to improved OS (HR 0.61, 95% CI 0.37-1.01); when the only trial which combined induction and maintenance thalidomide was excluded from this analysis, a significant survival advantage emerged (HR 0.49, 95% CI 0.32-0.74). The relative risk of venous thromboembolism (VTE) with induction thalidomide was 2.56 (95% CI 1.88-3.49). A meta-analysis of trials/sub-groups administering low molecular weight heparin (LMWH) as VTE prophylaxis, suggested a persistently increased relative risk of VTE with induction thalidomide (RR 1.54, 95% CI 1.07-2.22). The relative risk of VTE was substantially lower, but still elevated, when thalidomide was given as maintenance therapy following ASCT (RR 1.95, 95% CI 1.15-3.30). In summary, thalidomide appears to improve the overall survival of patients with newly diagnosed myeloma both when it is added to standard, non-transplantation therapy, and when it is given as maintenance therapy following ASCT. However, thalidomide is associated with toxicity, particularly a significantly increased risk of of VTE."
Fin de la cita.
Saludos.

Gracias por este artículo, Annie.

Un beso.

Gracias a ti por darme las gracias..
Vuelvo a decir igual que en el mensaje de :
"Secondary Genomic Rearrangements Involving Immunoglobulin "
Cita:
"La verdad, es que son "un poco rollo"          todos estos datos!        ..Me estoy pensando ponerlos en el foro,la proxima vez que los reciba  !"
Un gran abrazo

Te contesto igual que antes!!  

Besos.   

Vale!
  JAJA!